AIM ImmunoTech Inc.
AIM- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946644
In the last 90 days, AIM ImmunoTech Inc. insiders filed 10 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 13, 2026, 1:16 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $14.0M (15861.4% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Revenue | $88.0K | $170.0K | $202.0K | $141.0K | $135.0K |
| Research and development | $3.92M | $6.20M | $10.9M | $6.99M | $7.67M |
| Selling, general and administrative | $7.70M | $13.7M | $21.1M | $13.1M | $8.67M |
| Operating income | -$11.7M | -$19.8M | -$31.9M | -$19.9M | -$18.8M |
| Interest expense | $812.0K | $585.0K | – | – | $67.0K |
| Net income | -$14.0M | -$17.3M | -$29.0M | -$19.4M | -$19.1M |
| EPS, basic | $-8.62 | $-0.31 | $-0.60 | $-0.40 | – |
| EPS, diluted | $-8.62 | $-0.31 | $-0.60 | – | – |
| Weighted shares, basic | 1.62M | 56.0M | – | – | – |
| Weighted shares, diluted | 1.62M | 56.0M | 48.6M | – | – |
| Margins and growth | |||||
| Operating margin | -13254.5% | -11630.6% | -15800.0% | -14129.8% | -13954.1% |
| Net margin | -15861.4% | -10188.2% | -14337.6% | -13790.8% | -14168.1% |
| Revenue growth, year over year | −48.2% | −15.8% | +43.3% | +4.4% | −17.2% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Cash and equivalents | $2.98M | $1.70M | $5.44M | $27.1M | $32.1M |
| Short-term investments | $62.0K | $2.28M | $7.63M | $7.14M | $16.2M |
| Accounts receivable | $7.00K | – | $1.18M | – | – |
| Total current assets | $3.29M | $4.18M | $14.6M | $36.3M | $50.2M |
| Property, plant and equipment | $71.0K | $108.0K | $127.0K | $195.0K | $4.05M |
| Intangible assets | $1.66M | $2.59M | $2.31M | $1.94M | $1.97M |
| Total assets | $5.78M | $8.61M | $19.4M | $40.5M | $57.7M |
| Accounts payable | $1.63M | $6.38M | $6.44M | $377.0K | $198.0K |
| Short-term debt | $3.55M | $2.31M | – | – | – |
| Total current liabilities | $6.22M | $9.54M | $8.65M | $1.36M | $673.0K |
| Long-term debt | $927.0K | $2.81M | – | – | – |
| Total liabilities | $15.6M | $9.93M | $9.15M | – | – |
| Shareholders' equity | -$9.78M | -$1.32M | $10.2M | $38.5M | $56.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Operating cash flow | -$11.0M | -$14.9M | -$21.3M | -$16.1M | -$14.0M |
| Capital expenditures | – | $18.0K | – | $86.0K | $41.0K |
| Free cash flow | – | -$14.9M | – | -$16.2M | -$14.0M |
| Stock-based compensation | $60.0K | $686.0K | $243.0K | $954.0K | $1.57M |
| Investing cash flow | $1.85M | $4.71M | -$832.0K | $11.0M | -$631.0K |
| Financing cash flow | $10.4M | $6.44M | $485.0K | $80.0K | $8.19M |
| Net change in cash | $1.28M | -$3.74M | -$21.6M | -$5.04M | -$6.41M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 68.2% | 403.5% | 120.3% | 676.6% | 1161.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 11, 2026 | 39.9M | +1,299.2% | SEC |
| Aug 7, 2026 | 30.4M | +1,023.9% | SEC |
| May 13, 2026 | 14.6M | −80.9% | SEC |
| Mar 25, 2026 | 8.15M | −88.7% | SEC |
| Nov 14, 2025 | 2.85M | −95.5% | SEC |
| Aug 12, 2025 | 2.71M | −95.3% | SEC |
| May 13, 2025 | 76.4M | +49.0% | SEC |
| Mar 24, 2025 | 72.3M | +44.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-100 in Q2 2025.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.